Medication comparison for folliculitis decalvans
Treatments studied
Part of Skin clinical trials.
This trial compares three medications (adalimumab, ustekinumab, and baricitinib) to see which works better for a chronic scalp condition called folliculitis decalvans. It's for people who haven't gotten better with antibiotics and aims to reduce inflammation and hair loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 64 years old.
- Your folliculitis decalvans diagnosis must be confirmed by a skin biopsy.
- You must have tried at least two different antibiotic treatments in the past 2 years without enough improvement.
- You must have a chest X-ray done within the last 3 months that is normal.
- You must be able to speak and understand French.
- You must not have heart disease, a history of cancer (except certain skin cancers), or severe kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two medications, secukinumab and tofacitinib, to see which works better for moderate to severe hidradenitis suppurativa (a skin condition causing painful bumps) in Chinese patients. The goal is to find a more effective treatment option.
This trial tests a cream called delgocitinib for a type of hair loss that affects the front of the scalp and eyebrows. The cream may help reduce redness and scaling and potentially slow or stop the hair loss.
This study tests if baricitinib (a daily pill) is better than methotrexate (a common treatment) at reducing skin tightening in people with a severe type of scleroderma called diffuse cutaneous systemic sclerosis. It may help if your skin is getting tighter and you have been diagnosed in the last 5 years.
This study compares two biologic medicines, ustekinumab and upadacitinib, to see which works better for people with Crohn's disease that hasn't improved with other treatments. The goal is to reduce inflammation and help you feel better.
This trial tests two different medicines, infliximab and upadacitinib, to see which works better for people with severe ulcerative colitis that hasn't improved after 3 days of IV steroids. The goal is to find the best rescue option to help you feel better and avoid surgery.
This study compares the effectiveness of a pill (upadacitinib) with several biologic injections (biologics are medicines that target specific parts of the immune system) in controlling moderate-to-severe atopic dermatitis (eczema). The goal is to see which treatment helps people achieve minimal disease activity, meaning their eczema is under good control.
Hear when a new Folliculitis Decalvans (FD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.